Whitepaper: The Impact of Covid-19 on Life Sciences
The COVID-19 pandemic has upended the working norms of every sector, but perhaps no industry has been challenged quite so much as those businesses in life sciences. The importance of speed, and expediting the drug documentation approval process, took on a whole new meaning during the pandemic.
Yseop's new whitepaper looks at how recent global events have served as a catalyst for change for pharmaceutical companies. It has fundamentally altered the drug application approval process and introduced the rise of new technologies, like AI and NLG. Firms have had to pivot to new strategies like:
- How to automate parts of the drug introduction process without cutting corners
- Ways to leverage automation while still meeting strict regulatory requirements
- Tips to overcome cultural barriers related to AI adoption and acceptance
In this whitepaper, we look at the rise of new strategies that help firms get drugs to market safely, challenges this technology faces from the people who use it, and the opportunity to rewrite processes for the future.